Johnson & Johnson (JNJ) 101.46 $JNJ
3 Stocks to Watch in the Changing Landscape of ADHD Drugs
Leo Sun, The Motley Fool - Motley Fool - Sun Jun 01, 10:05AM CDT
A March report from pharmacy benefit manager Express Scripts revealed that U.S. prescriptions for adult attention deficit hyperactive disorder drugs rose from 1.7 million in 2008 to 2.6 million in 2012 -- a 53% increase. That study, which analyzed...
Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients
at The Street - Sat May 31, 6:35AM CDT
Pharmacyclics and Johnson & Johnson's blood-cancer drug Imbruvica reduced the risk of dying by 57% compared to GlaxoSmithKline's Arzerra when used to treat elderly patients with relapsed chronic lymphocytic leukemia, according to results from a phase...
Should Johnson & Johnson Join the Buyout Boom?
Dan Carroll, The Motley Fool - Motley Fool - Fri May 30, 5:30PM CDT
Mergers and acquisitions have been all the rage in health care in 2014. Big pharma's taken over the spotlight recently, but medical device giants have joined in the game recently, and now major orthopedics and spine device maker Smith & Nephew ...
Update on Bayer's Xarelto - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 30, 5:20PM CDT
Bayer (BAYRY) announced that it submitted a Marketing Authorization Application for Xarelto in Japan.
Final Glance: Pharmaceuticals companies
AP - Fri May 30, 5:06PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
Final Glance: Medical Devices companies
AP - Fri May 30, 5:06PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Business Highlights
By The Associated Press - AP - Fri May 30, 4:55PM CDT
___
Hysterectomy Cancer Lawsuit: Bernstein Liebhard Notes Report Indicating Johnson & Johnson Was Warned About Morcellator Cancer Risks in 2006
PR Newswire - Fri May 30, 4:33PM CDT
As its investigation of morcellator cancer lawsuits (http://www.gynecaremorcellatorlawsuit.com/) continues, Bernstein Liebhard LLP notes the publication of a new report which indicates that Johnson & Johnson was warned about uterine cancer risks potentially associated with power morcellators eight years before a warning from the U.S. Food & Drug Administration (FDA) prompted the company to suspend sales of certain devices marketed by its Ethicon, Inc. unit. According to The Pittsburgh Business Times, Dr. Robert Lamparter, then a pathologist at Evangelical Community Hospital in Lewisburg, Pennsylvania, wrote to Johnson & Johnson in 2006, imploring the company to "reconsider the risk to the patient" posed by the use of power morcellators in surgeries to remove uterine fibroids. In another of several emails and letters written to Johnson & Johnson that year, the now-retired Dr. Lamparter voiced concern that using a morcellator when a uterine tumor was present "may lead to dissemination of the malignant tissue."
Dow Today: Johnson & Johnson (JNJ) Leads The Day Higher, Goldman Sachs Group (GS) Lags
at The Street - Fri May 30, 3:30PM CDT
The Dow component that led the way higher today was Johnson & Johnson (NYSE: JNJ ), which sported a 70-cent gain (+0.7%) bringing the stock to $101.46. Holding the Dow back today was Goldman Sachs Group (NYSE: GS ), which lagged the broader...
Research and Markets: Endothelial Dysfunction - Pipeline Review, H1 2014: Johnson & Johnson, Chugai Pharmaceutical Co., Ltd., Glucox Biotech AB & Stealth Pep
Business Wire - Fri May 30, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/ngqbsp/endothelial) has announced the addition of the "Endothelial Dysfunction - Pipeline Review, H1 2014" report to their offering.
Midday Glance: Pharmaceuticals companies
AP - Fri May 30, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri May 30, 12:19PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Johnson & Johnson Collaborates with Aduro BioTech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 30, 10:50AM CDT
Johnson & Johnson (JNJ) inked a global licensing deal with Aduro BioTech for developing new therapies to treat prostate cancer.
Shares of JNJ Up 11.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri May 30, 9:33AM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on February 10th, 2014 at $90.44. In approximately 4 months, Johnson & Johnson has returned 11.20% as of today's recent price of $100.57.
Early Glance: Pharmaceuticals companies
AP - Fri May 30, 9:29AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Fri May 30, 9:29AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Why Wall Street Hates Exelixis Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 9:18AM CDT
Stocks with a high short interest can signal that something is fundamentally wrong with the underlying company. By the same token, short-sellers aren't always correct in their assessment of a company, and their mistakes can lead to a rapid upward...
Endothelial Dysfunction - Pipeline Review, H1 2014: Johnson & Johnson, Chugai Pharmaceutical Co., Ltd., Glucox Biotech AB & Stealth Pep
M2 - Fri May 30, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c7mqjq/endothelial) has announced the addition of the "Endothelial Dysfunction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endothelial Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endothelial Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Johnson & Johnson - Chugai Pharmaceutical Co., Ltd. - Glucox Biotech AB - Stealth Peptides Inc. Scope - The report provides a snapshot of the global therapeutic landscape of Endothelial Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Endothelial Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Endothelial Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Endothelial Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/c7...ndothelial
Would You Rather: Short Johnson & Johnson or Buy Dendreon?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 30, 6:31AM CDT
Investing is often filled with tough choices and opportunity costs. This game segment from The Motley Fool's Where The Money Is poses a hypothetical question: Would you rather short Johnson & Johnson or buy Dendreon ? Healthcare...
Global Elephantiasis (Lymphatic Filariasis) Therapeutics Pipeline Report 2014
M2 - Fri May 30, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bt9h9z/elephantiasis) has announced the addition of the "Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Elephantiasis (Lymphatic Filariasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Elephantiasis (Lymphatic Filariasis) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Johnson & Johnson - Eisai Co., Ltd. - Anacor Pharmaceuticals, Inc. Scope - The report provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Elephantiasis (Lymphatic Filariasis) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Elephantiasis (Lymphatic Filariasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Elephantiasis (Lymphatic Filariasis) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/bt...phantiasis
3 Stocks to Watch in the Changing Landscape of ADHD Drugs
Leo Sun, The Motley Fool - Motley Fool - Sun Jun 01, 10:05AM CDT
A March report from pharmacy benefit manager Express Scripts revealed that U.S. prescriptions for adult attention deficit hyperactive disorder drugs rose from 1.7 million in 2008 to 2.6 million in 2012 -- a 53% increase. That study, which analyzed...
Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients
at The Street - Sat May 31, 6:35AM CDT
Pharmacyclics and Johnson & Johnson's blood-cancer drug Imbruvica reduced the risk of dying by 57% compared to GlaxoSmithKline's Arzerra when used to treat elderly patients with relapsed chronic lymphocytic leukemia, according to results from a phase...
Should Johnson & Johnson Join the Buyout Boom?
Dan Carroll, The Motley Fool - Motley Fool - Fri May 30, 5:30PM CDT
Mergers and acquisitions have been all the rage in health care in 2014. Big pharma's taken over the spotlight recently, but medical device giants have joined in the game recently, and now major orthopedics and spine device maker Smith & Nephew ...
Update on Bayer's Xarelto - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 30, 5:20PM CDT
Bayer (BAYRY) announced that it submitted a Marketing Authorization Application for Xarelto in Japan.
Final Glance: Pharmaceuticals companies
AP - Fri May 30, 5:06PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
Final Glance: Medical Devices companies
AP - Fri May 30, 5:06PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Business Highlights
By The Associated Press - AP - Fri May 30, 4:55PM CDT
___
Hysterectomy Cancer Lawsuit: Bernstein Liebhard Notes Report Indicating Johnson & Johnson Was Warned About Morcellator Cancer Risks in 2006
PR Newswire - Fri May 30, 4:33PM CDT
As its investigation of morcellator cancer lawsuits (http://www.gynecaremorcellatorlawsuit.com/) continues, Bernstein Liebhard LLP notes the publication of a new report which indicates that Johnson & Johnson was warned about uterine cancer risks potentially associated with power morcellators eight years before a warning from the U.S. Food & Drug Administration (FDA) prompted the company to suspend sales of certain devices marketed by its Ethicon, Inc. unit. According to The Pittsburgh Business Times, Dr. Robert Lamparter, then a pathologist at Evangelical Community Hospital in Lewisburg, Pennsylvania, wrote to Johnson & Johnson in 2006, imploring the company to "reconsider the risk to the patient" posed by the use of power morcellators in surgeries to remove uterine fibroids. In another of several emails and letters written to Johnson & Johnson that year, the now-retired Dr. Lamparter voiced concern that using a morcellator when a uterine tumor was present "may lead to dissemination of the malignant tissue."
Dow Today: Johnson & Johnson (JNJ) Leads The Day Higher, Goldman Sachs Group (GS) Lags
at The Street - Fri May 30, 3:30PM CDT
The Dow component that led the way higher today was Johnson & Johnson (NYSE: JNJ ), which sported a 70-cent gain (+0.7%) bringing the stock to $101.46. Holding the Dow back today was Goldman Sachs Group (NYSE: GS ), which lagged the broader...
Research and Markets: Endothelial Dysfunction - Pipeline Review, H1 2014: Johnson & Johnson, Chugai Pharmaceutical Co., Ltd., Glucox Biotech AB & Stealth Pep
Business Wire - Fri May 30, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/ngqbsp/endothelial) has announced the addition of the "Endothelial Dysfunction - Pipeline Review, H1 2014" report to their offering.
Midday Glance: Pharmaceuticals companies
AP - Fri May 30, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri May 30, 12:19PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Johnson & Johnson Collaborates with Aduro BioTech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 30, 10:50AM CDT
Johnson & Johnson (JNJ) inked a global licensing deal with Aduro BioTech for developing new therapies to treat prostate cancer.
Shares of JNJ Up 11.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri May 30, 9:33AM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on February 10th, 2014 at $90.44. In approximately 4 months, Johnson & Johnson has returned 11.20% as of today's recent price of $100.57.
Early Glance: Pharmaceuticals companies
AP - Fri May 30, 9:29AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Fri May 30, 9:29AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Why Wall Street Hates Exelixis Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 9:18AM CDT
Stocks with a high short interest can signal that something is fundamentally wrong with the underlying company. By the same token, short-sellers aren't always correct in their assessment of a company, and their mistakes can lead to a rapid upward...
Endothelial Dysfunction - Pipeline Review, H1 2014: Johnson & Johnson, Chugai Pharmaceutical Co., Ltd., Glucox Biotech AB & Stealth Pep
M2 - Fri May 30, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c7mqjq/endothelial) has announced the addition of the "Endothelial Dysfunction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endothelial Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endothelial Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Johnson & Johnson - Chugai Pharmaceutical Co., Ltd. - Glucox Biotech AB - Stealth Peptides Inc. Scope - The report provides a snapshot of the global therapeutic landscape of Endothelial Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Endothelial Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Endothelial Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Endothelial Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/c7...ndothelial
Would You Rather: Short Johnson & Johnson or Buy Dendreon?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 30, 6:31AM CDT
Investing is often filled with tough choices and opportunity costs. This game segment from The Motley Fool's Where The Money Is poses a hypothetical question: Would you rather short Johnson & Johnson or buy Dendreon ? Healthcare...
Global Elephantiasis (Lymphatic Filariasis) Therapeutics Pipeline Report 2014
M2 - Fri May 30, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bt9h9z/elephantiasis) has announced the addition of the "Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Elephantiasis (Lymphatic Filariasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Elephantiasis (Lymphatic Filariasis) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Johnson & Johnson - Eisai Co., Ltd. - Anacor Pharmaceuticals, Inc. Scope - The report provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Elephantiasis (Lymphatic Filariasis) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Elephantiasis (Lymphatic Filariasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Elephantiasis (Lymphatic Filariasis) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/bt...phantiasis
